menu
Non-invasive Detection of Immunotherapy Biomarkers using TruSight Oncology 500 (TSO500)The TruSight Oncology 500 (TSO500) plasma assay employs a hybrid capture-based approach targeting 523 clinically relevant genes and leverages unique molecular indices to enable ultra-low frequency detection of SNVs, Indels, and CNVs. This comprehensive cancer panel interrogates relevant cancer biomarkers with as little as 20-30 ng of cfDNA and demonstrates robust analytical performance.

Download our factsheet to learn more.

Related Services: